Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

VP-315 Induces Reductions in Tumor Size in Basal Cell Carcinoma

August 14th 2024

Treatment with VP-315 led to reductions in tumor size in patients with basal cell carcinoma.

Durvalumab-Based Combos Win EU Approval for Advanced/Recurrent Endometrial Cancer

August 14th 2024

Durvalumab plus chemotherapy, then durvalumab with or without olaparib, was approved in Europe for select advanced/recurrent endometrial cancer.

Emerging ADCs and Immunotherapy Shake Up Triple-Negative Breast Cancer Management

August 13th 2024

Linda T. Vahdat, MD, discusses the use of ADCs in metastatic TNBC and how neoadjuvant immunotherapy performs in patients with early-stage TNBC.

Subgroup Analysis Makes the Case for Earlier Liso-Cel Administration in R/R MCL

August 13th 2024

Manali Kamdar, MD, discusses responses with liso-cel according to prior lines of therapy and BTK inhibitor exposure in mantle cell lymphoma.

Dr Ducreux on Findings From the TRANSMET Trial in Colorectal Liver Metastases

August 12th 2024

Michel Ducreux, MD, PhD, discusses findings from the TRANSMET trial of chemotherapy plus liver transplantation in unresectable colorectal liver metastases.

Dr El-Jawahri on the Impact of Palliative Care on End-of-Life Care for AML and MDS

August 12th 2024

Areej El-Jawahri, MD, discusses a trial investigating a palliative oncology care model for patients with AML and MDS receiving nonintensive therapy.

Improved Patient Selection Will Pave the Way for ADC Optimization in HER2-Low and -Ultralow Breast Cancer

August 9th 2024

Erika P. Hamilton, MD, discusses the implications of the DESTINY-Breast06 trial for patients with HER2-low and -ultralow breast cancer.

RPS-Optimized Checkpoint Inhibition Bolsters pCR in Patients With Select Rare Breast Cancers

August 9th 2024

High pCR rates were observed for patients with uncommon breast cancer subtypes who received response-predictive subtype–optimized therapy.

Enfortumab Vedotin/Pembrolizumab Does Not Negatively Impact QOL in Metastatic Urothelial Cancer

August 9th 2024

Enfortumab vedotin plus pembrolizumab improved survival vs chemotherapy with no QOL detriment in previously untreated metastatic urothelial cancer.

CIRT Plus Durvalumab/Tremelimumab Is Safe in Advanced HCC With Macrovascular Invasion

August 8th 2024

CIRT plus durvalumab and tremelimumab was safe in patients with advanced hepatocellular carcinoma with macrovascular invasion.

Dr Bazhenova on Updated Data From the TRUST-I Trial of Taletrectinib in ROS1+ NSCLC

August 8th 2024

Lyudmila A. Bazhenova, MD, discusses updated efficacy data from the TRUST-I study of taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Olomorasib Plus Pembrolizumab Generates Antitumor Activity in KRAS G12C+ NSCLC

August 8th 2024

Olomorasib plus pembrolizumab demonstrated responses in first-line metastatic KRAS G12C–mutant non–small cell lung cancer.

Merck Discontinues KeyVibe-008 Trial of Vibostolimab/Pembrolizumab Plus Chemo in ES-SCLC

August 8th 2024

The KeyVibe-008 trial evaluating vibostolimab, pembrolizumab, and chemotherapy in extensive-stage small cell lung cancer has been discontinued.

Dr Linscott on Future Directions for utDNA Research in Bladder Cancer

August 8th 2024

Joshua Linscott, MD, PhD, discusses a study investigating the use of utDNA to predict MRD prior to rTURBT in NMIBC.

Dr Saad on the Association Between IL-7 SNPs and Immune-Related AEs in RCC

August 8th 2024

Eddy Saad, MD, MSc, discusses the association between an IL-7 SNP and immune-related AEs in patients with RCC who received immune checkpoint inhibitors.

Leveraging ADCs in Lung Cancer: Snapshot of Existing Challenges and Opportunities

August 7th 2024

Kashul Parikh, MBBS, discusses research efforts dedicated to leveraging antibody-drug conjugates with varying targets in lung cancer.

EO-3021 Generates Responses in Advanced Solid Tumors Likely to Express CLDN18.2

August 6th 2024

EO-3021 was safe and led to responses in advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2.

EMA Grants Orphan Drug Designation to SLS009 for R/R PTCL

August 6th 2024

The European Medicines Agency has granted orphan drug designation to SLS009 for relapsed/refractory peripheral T-cell lymphoma

FDA Accepts sNDA for Cabozantinib in Advanced Pancreatic and Extra-Pancreatic NETs

August 6th 2024

The FDA has accepted a supplemental new drug application for cabozantinib in advanced pancreatic and extra-pancreatic neuroendocrine tumors.

Residual Cancer Burden May Prognosticate Outcomes With Neoadjuvant Therapy in Prostate Cancer

August 6th 2024

Praful Ravi, MB, BChir, MRCP, discusses an analysis measuring residual cancer burden in localized prostate cancer after neoadjuvant therapy and surgery.